Product Center
2024 National Vaccine and Health Conference
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2024-04-22
- Views:
(Summary description)On April 20-21, the 2024 National Vaccine and Health Conference was held in Xiongan New Area, Hebei Province. Ab&B Bio brought its first product, the quadrivalent influenza virus subunit vaccine (Huierkangxin®, HRK-X®), to the event once again.
2024 National Vaccine and Health Conference
(Summary description)On April 20-21, the 2024 National Vaccine and Health Conference was held in Xiongan New Area, Hebei Province. Ab&B Bio brought its first product, the quadrivalent influenza virus subunit vaccine (Huierkangxin®, HRK-X®), to the event once again.
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2024-04-22 14:06
- Views:
On April 20-21, the 2024 National Vaccine and Health Conference was held in Xiongan New Area, Hebei Province. Ab&B Bio brought its first product, the quadrivalent influenza virus subunit vaccine (Huierkangxin®, HRK-X®), to the event once again.
The theme of this conference was "Standardization • Expansion • Innovation — Promoting the Construction of a Healthy China with High-Quality Immunization Services", focusing on the scientific and practical issues involved in the high-quality development of vaccine immunization services. More than 3,000 experts and scholars from medical and health institutions, scientific research institutes, and colleges and universities nationwide attended the conference in person, while over 20,000 vaccine and health professionals participated online to exchange research results, share practical experiences, and discuss optimization strategies.
The booth, featuring Ab&B Bio’s unique design, attracted numerous experts, academics, media representatives, and industry peers to stop by. Attendees expressed keen interest and high expectations for the quadrivalent influenza virus subunit vaccine!

The company’s senior leaders visited the booth to engage with experts and academics, demonstrating their sincerity and pragmatism in serving attendees from various sectors.
Representatives from the marketing department enthusiastically and professionally addressed inquiries from attendees about the quadrivalent influenza virus subunit vaccine! Using the on-site influenza virus model, they vividly demonstrated the key feature of the subunit influenza vaccine: its exclusive extraction of the effective antigens hemagglutinin (HA) and neuraminidase (NA).
In the report of the sub-venue "Progress and Application of Vaccine Clinical Trials", Director Pan Hongxing, director of the Vaccine Clinical Evaluation Institute of Jiangsu Provincial Center for Disease Control and Prevention, presented on "Progress in Clinical Evaluation of Domestic New Influenza Vaccines" and introduced the relevant progress of the domestic new quadrivalent subunit influenza vaccine from three aspects: the current status of influenza vaccine application in China and the world, the interim safety data of the Phase III clinical study of the domestic new quadrivalent subunit influenza vaccine, and the scientific research project of the National Evaluation Center.

Since its establishment in 2005, Ab&B Bio has been committed to the R&D, production, and sales of innovative human vaccines. HRK-X®, now commercially available, is China’s first quadrivalent subunit influenza vaccine and is registered as a Class 1 preventive biological product. Ab&B Bio actively contributes to vaccine immunization advancements and the construction of a healthy China, while supporting influenza prevention and control efforts to ensure broader access to safer, more efficient influenza vaccines.
Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us